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ABSTRACT
Background
Transplantation of embryonic pig pancreatic tissue as a source of insulin has been suggested
for the cure of diabetes. However, previous limited clinical trials failed in their attempts to treat
diabetic patients by transplantation of advanced gestational age porcine embryonic pancreas.
In the present study we examined growth potential, functionality, and immunogenicity of pig
embryonic pancreatic tissue harvested at different gestational ages.
Methods and Findings
Implantation of embryonic pig pancreatic tissues of different gestational ages in SCID mice
reveals that embryonic day 42 (E42) pig pancreas can enable a massive growth of pig islets for
prolonged periods and restore normoglycemia in diabetic mice. Furthermore, both direct and
indirect T cell rejection responses to the xenogeneic tissue demonstrated that E42 tissue, in
comparison to E56 or later embryonic tissues, exhibits markedly reduced immunogenicity.
Finally, fully immunocompetent diabetic mice grafted with the E42 pig pancreatic tissue and
treated with an immunosuppression protocol comprising CTLA4-Ig and anti–CD40 ligand (anti-
CD40L) attained normal blood glucose levels, eliminating the need for insulin.
Conclusions
These results emphasize the importance of selecting embryonic tissue of the correct
gestational age for optimal growth and function and for reduced immunogenicity, and provide
a proof of principle for the therapeutic potential of E42 embryonic pig pancreatic tissue
transplantation in diabetes.
The Editors’ Summary of this article follows the references.
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Diabetes mellitus is a severe and debilitating chronic
disease that develops in nearly 5% of the world’s population
[1,2]. For all patients who have type 1 diabetes (insulin
deﬁciency due to autoimmune destruction of beta cells) or
severe type 2 diabetes (impaired insulin secretion combined
with reduced sensitivity to insulin), the only practical treat-
ment possible today is lifelong insulin replacement by
multiple daily injections. However, even for very compliant
patients participating in a carefully titrated insulin therapy
protocol aimed at avoiding glycemic ﬂuctuations, it is
difﬁcult to tightly control blood glucose levels. Thus, severe
microvascular complications associated with the disease may
develop [3–6]. Transplantation of an entire pancreas or
pancreatic islets would potentially beneﬁt millions of such
patients [7–13]. Unfortunately, this alternative is extremely
limited by the shortage of human donor organs available for
transplantation [14–16].
Considering the ethical limitations associated with imple-
mentation of new strategies for islet allotransplantation, such
as from human embryonic tissues, and the ongoing debate
regarding the use of human embryonic stem cells or adult
pancreatic stem cells for transplantation, the use of porcine
tissues might potentially provide an attractive, unlimited
source of pancreatic tissue [17].
Several safety concerns, in particular the potential hazards
associated with endogenous porcine retroviruses, have
presented major obstacles to such xenotransplantation [18–
20]. However, it is important to note that previous pig-to-
human xenotransplantations have not revealed a single
instance of porcine retrovirus transmission to a human [21].
Moreover, a recent study has suggested that these viruses
could be eradicated from pig herds bred speciﬁcally for
xenotransplantation [22]. Thus, as argued recently by Ogata
and Platt [23], although the potential threat of porcine
retroviruses to public health cannot be entirely dismissed, it
should be approached by careful attention to the xenograft
recipients, rather than being a reason for abandoning the
xenotransplantation approach.
A second major challenge, which still represents a major
obstacle for xenotransplantation, is the immune barrier [23].
However, the reduced immunogenicity of embryonic tissues
[24–26] might be advantageous in ameliorating rejection
following implantation of pig embryonic pancreas.
In the present study, we evaluated in the NOD-SCID mouse
model the ability of embryonic pig pancreatic tissue obtained
at different gestational time points to grow and secrete
insulin for prolonged time periods, and we further tested the
grafts’ ability to normalize blood glucose levels in diabetic
mice. An optimal ‘‘window of opportunity’’ was deﬁned by
measuring both the growth potential of the graft and its
ability to avoid graft rejection. The latter was evaluated by
using models for both the direct and indirect rejection
pathways.
Methods
Animals
Animals were maintained under conditions approved by
the Institutional Animal Care and Use Committee at the
Weizmann Institute of Science. Immune-deﬁcient NOD-SCID
mice aged 8–10 wk were used as hosts for the studies of graft
growth, and C57BL/6 mice were used as immunocompetent
mice for rejection studies; all mice were obtained from the
Weizmann Institute Animal Breeding Center (Rehovot,
Israel). For evaluation of rejection pathways, CBA/CaHN-
Btk XID mice and CD1-Hfh11 nude mice were purchased
from the Roscoe B. Jackson Memorial Laboratory (Bar
Harbor, Maine, United States). All mice were maintained in
small cages (up to ﬁve animals in each cage) and fed sterile
food and acid water containing ciproﬂoxacin (20 lg/ml).
Porcine Embryonic Pancreatic Tissues
Pig embryos were obtained from the Lahav Institute of
Animal Research (Kibbutz Lahav, Israel). Pregnant sows were
operated on at precisely deﬁned stages of their pregnancy
(embryonic day 24 [E24], E28, E42, E56, E80, and E100) under
general anesthesia, and embryos were extracted. Warm
ischemia time was less than 10 min, and the embryos were
transferred in cold phosphate buffered saline. Pig pancreas
precursors for transplantation were extracted under a light
microscope and maintained under sterile conditions at 4 8C
in RPMI 1640 (Biological Industries, Beit Haemek, Israel)
pending transplantation. Cold ischemia time until trans-
plantation was less than 2 h. The study protocol was approved
by the ethics committees at both the Weizmann Institute of
Science and the Lahav Institute of Animal Research.
Transplantation Procedure
Implantation of pig embryonic pancreas was performed
under general anesthesia with 2,2,2-tribromoethanol 97%
(2.5% Avertin in phosphate buffered saline; Sigman-Aldrich;
http://www.sigmaaldrich.com) at a dose of 10 ml/kg injected
intraperitoneally. Host kidney was exposed through a left
lateral incision. A 1.5-mm incision was made at the caudal
end of the kidney capsule, and the whole organ or a single
fragment (depending on gestational age) of the pancreatic
tissue, 1–2 mm in diameter, was grafted. Each group studied
included 5–7 grafted mice with donor tissue of distinct
gestational age exposed to various experimental conditions.
Glucose Challenge Test
Mice fasted 10–12 h were injected intraperitoneally with
glucose (3 g/kg) 6 wk after transplantation. Blood was
withdrawn from the retro-orbital sinus before (T0) and 30
min after (T30) glucose administration, and tested for both
glucose (Accu-check glucose sticks; Roche; http://www.roche.
com/home.html) and pig insulin levels (measured by ELISA).
In diabetic NOD-SCID mice the test continued for 150 min.
Induction of Diabetes
To determine the capacity of the pig embryonic pancreatic
grafts to regulate hyperglycemia in mice, grafted (E42 pig
embryonic grafts 4 mo after grafting) and non-grafted
immune-deﬁcient NOD-SCID or C57BL/6 mice were intra-
venously injected with 90 mg/kg alloxan (Sigma-Aldrich).
Glucose levels were measured from blood collected from the
tip of the tail following alloxan treatment at different time
points. In a second model, intact NOD-SCID mice were
injected intraperitoneally with 35 mg/kg/d streptozotocin
solubilized in sodium citrate buffer (pH 4.5) (Sigma-Aldrich)
daily for 5 d. Transplantation of E42 pancreas was carried out
3 d after completing the streptozotocin injections, and only
in animals with a glucose level above 16.5 mmol/l on two
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(Lantus, Sanoﬁ-Aventis, Paris, France) was given intraperito-
neally between 8:00 and 10:00 A.M.B l o o dg l u c o s ew a s
measured twice weekly at noon time, while postponing the
daily insulin injections, and if the glucose level was less than
13.7 mmol/l on two consecutive tests, insulin administration
was withheld.
Isolation and Transfer of Human Peripheral Blood
Mononuclear Cells
Human peripheral blood mononuclear cells (hu-PBMCs)
were generated from buffy coats obtained from normal
volunteers, layered on Ficoll-Paque solution, and centrifuged
at 2,000 rpm for 20 min. Human cells (80 3 10
6), collected
from the interface layer, were injected intraperitoneally after
washing to NOD-SCID mice, 1–3 d following embryonic
pancreatic transplantation. Engraftment of hu-PBMCs was
analyzed by measuring human immunoglobin G (IgG) levels
in the mouse serum by ELISA, and by detection of CD45
human leukocytes in the peritoneal ﬂuid, 10–14 d after
infusion, by a FACS analyzer (Becton-Dickinson; http://www.
bd.com) using anti-human-leukocyte common antigen CD45/
FITC (clone T29/33; Dako; http://www.dako.com). Only mice
positive by ELISA for human IgG production or by FACS for
human immune cell engraftment were further analyzed.
Costimulatory Molecular Blockade
Following transplantation, grafted C57BL/6 mice were
treated with mouse CTLA4-Ig fusion protein (lot number
20204, Chimerigen Laboratories; http://www.chimerigen.com)
and anti-CD40L antibody (MR1, kindly provided by Prof.
Bruce Blazar, University of Minnesota, Minneapolis, Minne-
sota, United States) given intraperitoneally on days 0, 2, 4,
and 6 at doses of 200 lg/mouse (CTLA4-Ig) and 250 lg/mouse
(anti-CD40L). Single injections of CTLA4-Ig and anti-CD40L
were repeated every 2 wk. Control mice were injected with
phosphate buffered saline.
Histology and Immunohistochemistry
Tissue sections were routinely stained by Hematoxylin and
Eosin. Assessment of graft differentiation and function was
performed by histochemical and immunohistochemical label-
ing of 4-lm-thick parafﬁn sections after xylene deparafﬁni-
zation and rehydration. Endogenous peroxidase, in both
parafﬁn sections and 6- or 12-lm cryosections, was blocked
with 0.3% H2O2 in 70% methanol for 10 min. Antigen
retrieval procedures were performed according to the
manufacturer’s instructions for each antibody (see below).
After blocking, sections were incubated with speciﬁc ﬁrst
antibody for 1 h at room temperature. The following
antibodies were used: rabbit anti-human glucagon (Dako),
guinea pig anti-rabbit insulin (Dako), rabbit anti-human
pancreatic polypeptide (Dako), a cocktail of rabbit anti-
porcine a-amylase and bovine trypsin (Nordic Immunology,
Tilburg, Netherlands), mouse anti-human Ki67 (clone MIB-1;
Dako), mouse anti-human cytokeratin 20 (clone Ks 20.8;
Dako), mouse anti-human CD45 (clones 2B11 and PD7/26;
Dako), polyclonal rabbit anti-human CD3 (Dako), mouse anti-
human CD20cy (clone L26; Dako), mouse anti-human CD68
(clone KP1; Zymed Laboratories, San Francisco, California,
United States), mouse anti-pig CD45 (MCA1447; Serotec,
Oxford, United Kingdom), and rat anti-mouse F4/80 antigen
(Serotec). Detection of antibody binding was performed using
the following secondary reagents: Dako peroxidase envision
system for detection of mouse and rabbit antibodies and
Sigma biotinylated anti-goat antibody (followed by extra-
avidin peroxidase reagent) for detection of goat antibodies.
For all peroxidase-labeled sections, diaminobenzidine was
used as the chromogen. Tissue sections were counterstained
with Hematoxylin.
For triple immunoﬂuorescent labeling with ﬁrst antibodies
including mouse anti-human Ki67, guinea pig anti-rabbit
insulin, and a cocktail of rabbit anti-porcine a-amylase and
bovine trypsin, the following secondary antibodies were
applied: Texas Red conjugated donkey anti-mouse antibody
(Jackson ImmunoResearch Laboratories, West Grove, Penn-
sylvania, United States), biotinylated donkey anti–guinea pig
antibody following streptavidin aminomethylcoumarin (Jack-
son ImmunoResearch Laboratories), and Cy2 conjugated goat
anti-rabbitantibody (Jackson ImmunoResearch Laboratories).
For all immunohistochemical stainings, a negative control was
run using the same technique but omitting the primary
antibody, while adding the labeled secondary antibody.
ELISA Measurements of Pig Insulin
The porcine/human insulin kit (K6219, Dako), in which the
primary pig anti-insulin antibody does not cross-react with
mouse insulin, was used to follow pig insulin levels according
to the manufacturer’s instructions. Mice serum samples were
loaded in a blinded fashion into the wells.
Statistical Analysis
Differences between groups were evaluated by the Stu-
dent’s t-test. Data are expressed as mean 6 standard
deviation and are considered statistically signiﬁcant if p-
values were 0.05 or less.
Results
Growth Potential and Functionality of Pig Embryonic
Tissue Obtained at Different Gestational Time Points
Earlier studies in SCID mice, in which pig embryonic
pancreatic tissue obtained at different gestational ages was
implanted and observed for 6 wk, indicated that optimal
growth potential is exhibited by the tissue harvested in the
E42–E56 period [27]. To further ascertain the utility of E42–
E56 tissue as a source for transplantation, we initially tested
the response of the growing implants in NOD-SCID mice to
glucose challenge 6 wk after transplantation. A summary of
ten independent experiments is shown in Figure 1; in each
experiment, pig pancreatic implants using embryonic tissues
of two or more gestational ages were compared. Glucose
levels and pig insulin secretion were determined before (T0)
and 30 min after (T30) glucose administration to fasting
transplanted mice. Only mice exhibiting a glucose level above
16.5 mmol/l at T30 were included. Average glucose levels at T0
and T30 were 3.5 6 0.55 and 26.5 6 3.7 mmol/l, respectively (p
, 0.001), in all tested mice. A considerably higher pig insulin
level at T30 compared to T0 was detected upon glucose
stimulation of the mice implanted with E42 or E56 tissue (p ,
0.001 and p , 0.005, respectively) while glucose stimulation of
mice with earlier (E24 and E28) or later (E100) gestational age
pancreatic grafts resulted in only minor elevation of pig
insulin levels, which was not statistically signiﬁcant when
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E80 pig pancreatic grafts demonstrated signiﬁcant elevation
in pig insulin secretion following glucose stimulation (T0
versus T30, p , 0.02), the total level of pig insulin was
signiﬁcantly lower than the level secreted by the E42 or E56
implants at T30 (p , 0.002 and p , 0.004, respectively). A
signiﬁcant difference was also noted when comparing the
levels of pig insulin secreted at T30 by the E42 and E56 grafts
to those secreted by grafts of earlier gestational ages (E24 and
E28) (p , 0.01 and p , 0.006, respectively). No signiﬁcant
difference was noted when comparing the T30 insulin levels
secreted by the E42 versus the E56 pancreatic implants.
However,thebloodlevelsofpiginsulinintherecipientmice
at 6 wk post-transplant were insufﬁcient to control hyper-
glycemia; therefore, it was of interest to further characterize
the gestational ‘‘window’’ by evaluating long-term growth and
functionality, as well as the immunogenicity of embryonic
tissues harvested at different gestational time points.
Prolonged functional follow-up of the grafted growing
tissue when tested at 3 and 4 mo post-transplant revealed an
even greater difference when comparing basal serum pig
insulin levels secreted by the E42 and E56 grafts with earlier
or later gestational age grafts (Figure 2A). Thus, 12 wk after
transplantation, the average pig insulin levels secreted by the
E42 and the E56 implants were 85.8 6 49.8 and 121.2 6 67.8
pmol/l, respectively, while the E80 implants yielded an
average insulin level of only 9.6 6 6.6 pmol/l (p , 0.001). At
16 wk post-transplant, the E80 implants secreted negligible
levels of pig insulin (3 6 1.2 pmol/l). Although the pig insulin
levels secreted by E28, E42, and E56 implants increased over
time, signiﬁcant differences were found when comparing the
E28 and the E42 pig insulin levels at 12 and 16 wk after
transplantation (p , 0.004 and p , 0.003, respectively) and
when comparing the pig insulin levels secreted by the E56 and
E28 implants at the same time points following transplant (p
, 0.007 and p , 0.04, respectively), whereas comparison of
the pig insulin levels secreted by the E42 and E56 grafts at 6,
12, and 16 wk after transplantation showed no signiﬁcant
difference. Ten months’ follow-up of pig insulin blood levels
after implantation of E42 tissue revealed a steady state
beyond the 4-mo time point (data not shown). The impressive
growth of E42 pig pancreatic tissue is shown in Figure 2B,
which shows an implant of about 1 mm
2 placed under the
renal capsule that reached a size of 50 mm
2 (Figure 2B, panel
A) 5 mo after transplantation and was composed of normal-
looking large islets (Figure 2B, panel B). The islets were
closely adjacent to each other, surrounded by the pancreatic
mesenchyme and fat. Typically, most of the islets expressed
insulin, glucagon, and pancreatic polypeptide (Figure 2B,
panels C, D, and E, respectively). Epithelial cells within the
graft were stained for cytokeratin 20, known for its selective
binding to pig pancreas epithelium [28], thereby indicating
the speciﬁc donor origin of this tissue (Figure 2B, panel F).
Taken together, our data show that an optimal gestational
‘‘window’’ is provided by the E42–E56 pig embryonic
pancreas, exhibiting the most favorable potential to grow
and differentiate into functional islets in NOD-SCID mice.
However, this ‘‘window’’ could still be further deﬁned by
comparing the immunogenicity of E42 and E56 implants.
Differential Immunogenicity of Pig Embryonic Tissue
Obtained at the E42 and E56 Gestational Time Points
A major potential advantage of embryonic tissue implan-
tation is its reduced immunogenicity [24,25]. We demon-
strated recently that marked differences in immune response
are observed when pig or human embryonic kidney precursor
tissues of different gestational ages are implanted in
immunodeﬁcient mice reconstituted with human lympho-
cytes [29]. Using the same approach, we tested the potential of
the E42 and E56 pig pancreatic grafts to induce rejection by
such ‘‘humanized’’ SCID mice.
In this model, engraftment of the hu-PBMCs in the NOD-
SCID mice was documented by FACS analysis of human
CD45-positive cells in the peritoneal ﬂuid and by detection of
human IgG in the serum of implanted mice using a human-
IgG-speciﬁc ELISA (average IgG concentration: 60.7 6 7.4
mcg/ml). Only mice positive for human IgG and for the
presence of human CD3 cells were included. In each experi-
ment, engraftment and growth of the fetal pig tissue
implanted in NOD-SCID mice in the presence or absence
of hu-PBMCs was monitored by ELISA for serum pig insulin
levels. Figure 3 summarizes four experiments in which the pig
insulin levels detected in the serum of grafted SCID mice
were compared to those found in the grafted ‘‘humanized’’
SCID mice 4 wk after transplantation of E42 or E56 pig
pancreatic tissue. As can be seen, in the absence of hu-
PBMCs, similar pig insulin levels were found in NOD-SCID
mice transplanted with E42 and E56 tissues (17.4 6 7.2 and 21
6 7.8 pmol/l, respectively). However, adoptive transfer of hu-
PBMCs to the grafted NOD-SCID mice caused a signiﬁcant
reduction in the pig insulin level secreted by the E56 grafts
relative to E56-grafted NOD-SCID mice in the absence of hu-
PBMCs (5.76 6 3 versus 21 6 7.8 pmol/l, p , 0.001), whereas
only a slight decrease in pig insulin levels was noted upon
implantation of E42 pig pancreas in conjunction with hu-
PBMCs (17.4 6 7.2 versus 13.2 6 5.4 pmol/l, p . 0.05).
Similarly, the pig insulin level secreted by the E42 grafts in
mice reconstituted with hu-PBMCs was signiﬁcantly higher
than that secreted by the E56 grafts implanted under similar
conditions (13.2 6 5.4 versus 5.76 6 3 pmol/l, p , 0.001). The
continuous insulin production in the E42 grafts in the
presence of hu-PBMCs in contrast to the signiﬁcant reduc-
tion of insulin secretion exhibited by E56 grafts indicates that
indeed the earlier embryonic grafts are less immunogenic.
Figure 1. Pig Insulin Secretion by Embryonic Pancreatic Precursors of
Different Gestational Ages Transplanted under the Kidney Capsule of
NOD-SCID Mice in Response to Glucose Stimulation
Mice were tested 6 wk after transplantation, and pig insulin levels were
measured before (T0) and 30 min after (T30) glucose challenge. Each dot
represents one mouse. Groups of mice grafted with E24, E28, E42, E56,
E80, and E100 donor pancreatic tissues included seven, 11, 16, 14, 13,
and seven recipients, respectively.
DOI: 10.1371/journal.pmed.0030215.g001
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tional age pig pancreatic tissue was further demonstrated by
histological data speciﬁcally characterizing the subpopula-
tions of the different inﬂammatory cells (panleukocytes, T
and B lymphocytes, and macrophages) within the grafts. In
contrast to the minimal hu-PBMC inﬂammatory cells
observed within the E42 pig embryonic pancreatic grafts, an
extensive hu-PBMC inﬁltrate was found within the E56 pig
pancreatic grafts, leading to irreversible destruction of the
graft (data not shown). Thus, although E42 and E56 pig
pancreatic tissues exhibit similarly optimal growth potential,
the less immunogenic E42 tissue likely represents the overall
optimal pig embryonic source for transplantation.
E42 Implants Are Predominantly Composed of Endocrine
Tissue with Minimal Exocrine Activity
A major concern associated with pancreatic tissue implan-
tation is how to avoid destruction of the growing organ by the
local release of proteolytic enzymes, which might be released
by the exocrine components of the implant. Therefore, we
characterized the development and the proliferative poten-
tial of the endocrine and the exocrine embryonic pancreatic
structures before and after transplantation of tissues har-
vested at various time points. Endocrine and exocrine
elements were identiﬁed by immunostaining for insulin (as
a marker for endocrine expression) or for trypsin and
amylase (markers of exocrine expression); both types of cells
were also stained for expression of Ki67 (a proliferation
marker). When analyzing the embryonic tissues before trans-
plantation (E28 to E80), the highest amount of insulin-
containing islet-like structures, within which many cells
coexpressed Ki67, was found in the E42 and E56 embryonic
pancreas, indicating that at this stage a substantial population
of cells could both proliferate and secrete insulin. At E80, the
number of cells expressing both insulin and Ki67 markedly
decreased, and multiple cells expressing trypsin and amylase
were observed (data not shown).
Figure 2. Pig Insulin Secretion and Histological Appearance of Long-Standing Embryonic Pancreatic Grafts
(A) Pig insulin levels following transplantation of E28, E42, E56, and E80 pig pancreas tissues under the kidney capsule of NOD-SCID mice. The data are
based on average 6 standard deviation pig insulin level measured in seven independent experiments, each of which includes comparison among pig
pancreatic precursors of two to three different gestational ages (*, p , 0.05; ***, p , 0.005; comparing E42 or E56 with E28 pig insulin levels).
(B) E42 pig pancreatic grafts 5 mo after transplantation under the kidney capsule of NOD-SCID mice. Macroscopic appearance reveals a large viable graft
that covers the kidney and contains abundant blood vessels (panel A); the graft is marked by an arrow. Histological analysis of the grafts demonstrates
mainly dense islets of different sizes (panel B) (Hematoxylin and Eosin staining; islets marked by arrows). The ability of these islets to produce hormones
is evident by positive staining for insulin (panel C), glucagon (panel D), and pancreatic polypeptide (panel E). Close proximity between islets and ducts is
occasionally seen (panel C, magnified inset). The epithelial cells are widely stained for cytokeratin 20 (panel F).
DOI: 10.1371/journal.pmed.0030215.g002
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endocrine structures within the growing E42 grafts (Figure 4)
was entirely different from that observed in the adult pig
pancreas, which is largely composed of exocrine tissue. As
shown in Figure 4A, only a minimal level of exocrine cells was
detected in the E42 graft 3 mo after transplantation, and
most of the cells were of the endocrine lineage. Compared to
the pretransplant E42 tissue, a decreased level of proliferat-
ing cells was noted, and the majority of the proliferating cells
coexpressed insulin (arrows) and not trypsin or amylase. The
disappearance of the exocrine tissue was even more
pronounced at 6 mo post-transplant (Figure 4B), at which
time the graft was composed mainly of insulin-producing
cells and exhibited a further decrease in proliferative
potential (arrow). When evaluated in very long-term grafts
at 8 mo (Figure 4C) and 10 mo (Figure 4D) after trans-
plantation, no evidence of exocrine cells was found, and the
grafts were completely occupied by enlarged islet structures
not expressing proliferation markers.
Normalization of Blood Glucose Levels by E42 Pig
Pancreatic Tissue
To determine the capacity of the pig embryonic pancreatic
graft to control hyperglycemia in transplanted mice, we
initially allowed the implanted tissue to grow and develop,
and then we induced diabetes in the grafted NOD-SCID by
alloxan [30]. This approach is based on the selective toxicity
of alloxan, which destroys rodent, but not human or porcine
beta cells, a circumstance that enabled us to assess the
potential of the pig pancreatic implant to sustain normal
glucose levels in a recipient whose own pancreas was
practically destroyed [31,32].
Experiments included 17 recipient mice grafted with
growing E42 pig embryonic pancreas, 4 mo after transplant,
followed for pig insulin level by ELISA, and 13 control non-
grafted NOD-SCID mice. Both groups were intravenously
Figure 3. Insulin Secretion following Transplantation of E42 and E56 Pig
Embryonic Pancreatic Tissues in the ‘‘Humanized’’ SCID Mouse Model
Pig insulin levels were measured 4 wk after transplantation of E42 and
E56 pig pancreas into NOD-SCID mice in the absence (black bars) and
presence (grey bars) of 80310
6 adoptively transferred hu-PBMCs infused
into the grafted mice 1–3 d after transplant. Four experiments were
carried out, each comparing pig insulin levels secreted by the grafts from
two gestational time points. The bars represent average 6 standard
deviation pig insulin levels measured in all experiments. The number of
grafted NOD-SCID mice without and with hu-PBMCs, respectively, was as
follows: 19 and 17 for E42, and 15 and 14 for E56.
DOI: 10.1371/journal.pmed.0030215.g003
Figure 4. Expression of Endocrine, Exocrine, and Proliferative Markers in Long-Standing E42 Pig Pancreatic Grafts
E42 pig pancreatic tissue was transplanted into NOD-SCID mice. Grafts were histologically analyzed at 3 (A), 6 (B), 8 (C), and 10 mo (D) after transplant.
Endocrine expression is tracked by anti-insulin staining (blue), exocrine expression by anti-trypsin and anti-amylase staining (green), and proliferation
status by anti-Ki67 staining (red). Cells coexpressing insulin and Ki67 are marked by arrows (A and B).
DOI: 10.1371/journal.pmed.0030215.g004
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Embryonic Pancreas Transplantationinjected with alloxan. Glucose concentrations were followed
before and at various time points after alloxan injection.
Prior to alloxan treatment, average glucose levels were similar
in both grafted and control animals (5.6 6 0.6 and 6.2 6 1.1
mmol/l, respectively, p ¼ 0.2). Pig insulin levels were negative
in all control animals, while pig insulin levels in the E42-
pancreas-grafted mice ranged from 18 to 1,086 pmol/l.
Within 3 d following alloxan injection, three animals in the
control group had died, while the remaining ten survivors
exhibited high glucose levels, with an average of 29.1 6 5
mmol/l. The hyperglycemia persisted in all control mice,
which eventually died within 18 d after alloxan injection
(Figure 5A). Of the 17 grafted mice, 13 did not develop
hyperglycemia while four mice had glucose levels above 16.5
mmol/l after alloxan treatment. When analyzing the pig
insulin level at 16 wk after transplantation (before alloxan
injection), it was noted that the four mice who later failed to
control hyperglycemia exhibited the lowest pig insulin levels
(below 120 pmol/l), whereas in all 13 grafted mice exhibiting
normal blood glucose levels following alloxan treatment the
pig insulin level was above 120 pmol/l before alloxan
treatment. To conﬁrm the contribution of the graft to
normalization of glucose levels in the euglycemic alloxan-
treated grafted mice, grafts were removed by left nephrec-
tomy at 41 d after alloxan injection in ten mice and at 61 d
after alloxan injection in three mice, and blood glucose
measurements were taken thereafter. As can be seen in Figure
5A, this intervention resulted in irreversible hyperglycemia.
Figure 5. E42 Pig Pancreatic Tissue Normalizes Blood Glucose Levels in Diabetic Mice
(A) Glucose levels in durably grafted (E42 embryonic pancreas) and non-grafted alloxan-treated NOD-SCID mice. Grafted (blue lines) and non-grafted
(red lines) NOD-SCID mice were injected with alloxan 4 mo after transplantation. All non-grafted mice died within 2–18 d. Grafted mice exhibiting pig
insulin levels below 120 pmol/l prior to the alloxan treatment failed to control hyperglycemia (broken blue lines); however, grafted mice demonstrating
pig insulin levels above 120 pmol/l before alloxan injection maintained their glucose levels within the normal range (unbroken blue lines). Removal of
the left kidney bearing the pig pancreatic graft at 41 or 61 d after alloxan treatment caused irreversible hyperglycemia.
(B) Functionality of E42 pig pancreatic grafts in alloxan-treated NOD-SCID mice. After a 10-h fast period, 3 g/kg glucose was administered
intraperitoneally. Glucose (black line) and pig insulin (broken black line) were followed at different time points spanning 150 min. The data represent
three experiments and include 15 alloxan-treated NOD-SCID mice grafted with E42 pig pancreas evaluated 4 mo after transplant.
(C) Long-term follow-up of average glucose (black line) and pig insulin (broken black line) in streptozotocin-treated NOD-SCID mice grafted with E42
pig pancreas. Of 19 animals treated with streptozotocin, ten survived up to 14 wk following transplantation and eventually became independent of
exogenous insulin.
(D and E) Pig insulin is highly expressed in the alloxan- (D) and the streptozotocin-treated (E) NOD-SCID mice 4 mo after transplantation, as detected by
specific staining of nephrectomized kidneys bearing the E42 pancreatic grafts.
DOI: 10.1371/journal.pmed.0030215.g005
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respond to changes in glucose levels, grafted alloxan-treated
NOD-SCID mice were challenged with 3 g/kg glucose after
fasting. As can be seen in Figure 5B, a physiological pattern of
glucose levels and pig insulin secretion was found. The
elevation in average glucose level 30 min after the glucose
stimulation (4.3 6 0.9 versus 22 6 3 mmo/l, p , 0.001) was
followed by insulin elevation (210 6 120 versus 408 6 132
pmol/l, p , 0.04), resulting in a gradual decrease of glucose
level to a normal range, which was followed by insulin
decrease.
The potential of E42 pig tissue to normalize blood glucose
levels was also evaluated in NOD-SCID mice in which diabetes
was induced by streptozotocin prior to implantation; this
model resembles the clinical case when patients exhibit overt
diabetes before transplant. In these mice, insulin treatment
was required because of a glucose level above 13.8 mmol/l in
19 out of 19, 13 out of 15, nine out of 14, and two out of 12
surviving animals at 3, 5, 7, and 11 wk after transplantation,
respectively, until the graft size was sufﬁciently large to
secrete an average level of 228 6 60 pmol/l pig insulin into
the blood, a level usually achieved by 14 wk following
transplantation. At this point, ten out of ten surviving grafted
streptozotocin-treated mice were free of diabetes (highest
glucose level: 9.1 mmol/l). Up to this point, as can be seen in
Figure 5C, a gradual decrease in the glucose levels from 22.2
6 2.3 mmol/l at 3 wk post-transplant down to 7.7 6 1 mmol/l
at 14 wk post transplant (p , 0.001) was achieved. As in the
alloxan model, nephrectomy of the kidney bearing the
pancreatic graft was performed in ﬁve animals 3 wk after
cessation of the exogenous insulin treatment, resulting in
hyperglycemia (data not shown). Histology of the grafts
within the nephrectomized kidneys in both alloxan- (Figure
5D) and streptozotocin-induced (Figure 5E) diabetes models
revealed multiple islets embedded in fat and ﬁbrous tissue,
with no difference in their appearance and number per
microscopic ﬁeld.
Implantation of E42 Pig Pancreatic Tissue into Fully
Immune-Competent Recipients
Considering the low frequency of immature dendritic cells
in peripheral blood mononuclear cell preparations, the
‘‘humanized’’ mouse model, which lacks mouse T cells or
signiﬁcant levels of mature dendritic cells or other profes-
sional human antigen-presenting cells (APCs), is biased
towards measuring rejection mediated by the direct pathway
in which T cells recognize foreign antigens presented on
donor APCs [33,34]. However, in fully immune-competent
recipients, bearing normal levels of APCs as well as T cells,
such grafts could still be rejected through the indirect
pathway (cross-priming) in which host T cells recognize
foreign antigens presented on host APCs. Indeed, when
transplanted under the kidney capsule of fully immunocom-
petent mice in the absence of immune suppression, rejection
of E42 pancreatic implants was completed between 8 and 10 d
post-transplant, with ﬁbrosis and inﬁltration observed at the
implantation site, while implants in NOD-SCID recipients
were fully viable (Figure 6). Interestingly, all gestational age
embryonic pancreas tissues (E28 to E100) were subjected to
such prompt rejection when implanted in immune-compe-
tent mice. The rejection pattern of the E42 pig embryonic
implants was further tested in mouse strains with various
immune defects, including XID mice, in which B cell function
is impaired, and nude mice, which are almost completely
devoid of T lymphocytes. As seen in Figure 6C, complete
rejection was detected in the XID mice, similar to the
rejection pattern exhibited by normal C57BL/6 mice, while
marked growth and development were found upon implan-
tation of E42 tissue into nude mice (Figure 6D). These results
indicate that rejection of E42 pig pancreatic precursor tissue
is largely mediated by T cells, and is less affected by humoral
or natural killer responses.
The recognition that early embryonic kidney or pancreatic
tissues are more likely to trigger cross-priming than direct
recognition led us to investigate the role of costimulatory
blockade, previously shown to be effective in the xenotrans-
plantation model [35,36]. To this end, we evaluated pancre-
atic implant growth and function after transplantation of
E42, E56, and E80 pig pancreas into C57BL/6 mice in the
presence of costimulatory blockade with CTLA4-Ig and anti-
CD40L (administered on days 0, 2, 4, and 6 and thereafter
every 2 wk, as described in detail in Methods). When tested at
2 wk post-transplant, the E80 grafts were completely rejected
and the E56 grafts were heavily inﬁltrated, demonstrating
advanced tissue damage (data not shown). In contrast, fully
immune-competent recipients of E42 tissue, treated by
biweekly administration of CTLA4-Ig and anti-CD40L,
exhibited pig insulin blood levels similar to those found in
NOD-SCID mice over the course of 3 mo after transplant
(Figure 7A). These results, which strongly indicate that
rejection was avoided, were further conﬁrmed by histological
examination of the implants, which showed marked growth
and development with minimal inﬁltration of mouse T cells
or macrophages (Figure 7B). Interestingly, cessation of
treatment with the costimulatory agents resulted in reduced
pig insulin levels and rejection of the implants (data not
shown).
Similarly to NOD-SCID recipients of E42 pancreatic tissue,
when treated with alloxan 4 mo after transplantation, four
out of seven grafted C57BL/6 mice treated biweekly for up to
4 mo post-transplant with CTAL4-Ig and anti-CD40L were
Figure 6. Rejection of the E42 Pig Pancreas in Different Immunologically
Mutant Mice
Grafts of E42 pig pancreas were transplanted under the kidney capsule of
NOD-SCID (A), C57BL/6 (B), XID (C), and nude (D) mice and harvested 17
d after transplant. Note the extensive fibrosis and infiltration indicating
rejection in the C57BL/6 and XID mice, while pancreatic components are
seen in the NOD-SCID and nude mice. Each group included five mice.
DOI: 10.1371/journal.pmed.0030215.g006
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grafted alloxan-treated C57BL/6 mice exhibited irreversible
hyperglycemia (8.5 6 1.3 versus 31 6 1.9 mmol/l, p , 0.001).
Removal of the implants by nephrectomy in these four mice
led to a sharp increase in average glucose levels 2 d after the
surgical procedure (25.2 6 1.3 mmol/l). Taken together, these
results demonstrate that E42 pancreatic tissue can be func-
tionally engrafted in fully immunocompetent mice for
prolonged periods of time under an immune suppression
protocol based solely on costimulatory blockade agents.
Discussion
In the early 1990s, Groth et al. attempted to transplant
embryonic pig pancreatic tissue into a series of diabetic
patients [37]. In these attempts, which did not reverse
diabetes, they used pooled porcine fetal islet-like cell clusters
harvested between E66 and E81. Some evidence for porcine
islet survival was detected in biopsies, but the insulin levels
were not sufﬁcient to maintain normoglycemia in human
hosts. This outcome could be attributed either to rejection or
to a variety of technical difﬁculties associated with the
terminal condition of the patients, but the possibility that the
embryonic tissue had weak growth potential because it was
collected at a suboptimal gestation time should also be
considered. Recently [27], we assessed in NOD-SCID mice the
growth potential of several pig embryonic tissues obtained at
different gestational time points. For liver precursors,
optimal growth potential at 6 wk post-transplant was
exhibited by E28 tissue, while pancreas and lung grew
optimally if obtained at E42 and E56, respectively, with
marked decrease in pancreatic growth potential around E80,
the stage previously used for fetal islet-like cell cluster
transplantation by Groth et al.
In the present study, our early pancreatic transplantation
attempts have been extended over a long follow-up period,
and the transplant ‘‘window’’ was assessed by functional as
well as immunogenicity assays. Pig pancreatic tissue obtained
at the E42–E56 gestational window led to the highest pig
insulin blood levels in transplanted mice before and after
glucose challenge 6 wk after transplantation. Furthermore,
E42–E56 pancreatic tissue was found to secrete more pig
insulin 4 mo after transplantation than E28 tissue, which has
been previously advocated [38,39], and E80 tissue, as was used
Figure 7. Pig Insulin Secretion and Histological Findings of E42 Pig Embryonic Pancreas Transplanted in NOD-SCID and Immunocompetent Mice
Treated with Costimulatory Blockade
(A) Pig insulin secretion by E42 pig pancreatic grafts implanted under the kidney capsule of NOD-SCID mice (black bars) or C57BL/6 mice treated every 2
wk with CTLA4-Ig and anti-CD40L (grey bars). No pig insulin could be detected in negative control transplanted C57BL/6 mice in the absence of
immunosuppression, therefore these results are not shown. Each group included 13 mice.
(B) Histological findings 3 mo following E42 pig pancreas transplantation under the kidney capsule of NOD-SCID mice (panel A), immunocompetent
C57BL/6 mice (panel B), and C57BL/6 mice treated biweekly with CTAL4-Ig and anti-CD40L (panel C). Note the fierce rejection in C57BL/6 mice evident
by implant destruction and fibrosis in (panel B), while intact graft development is demonstrated in C57BL/6 mice treated with CTLA4-Ig and anti-CD40L
(panel C) revealing positive staining for insulin (panel D). A small number of mouse CD3 cells (panel E) and macrophages (panel F, stained by F4/80)
infiltrated the graft parenchyma (marked by arrowheads) without causing apparent damage to the pancreatic structures.
DOI: 10.1371/journal.pmed.0030215.g007
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[37,40]. Considering that such clusters are less effective in
general than entire tissue, likely because of the importance of
stromal elements [41], the poor growth potential exhibited by
E80 intact tissue fragments indicates that clusters isolated
from E80 tissue will be even less effective.
The ﬁnal choice between E42 and E56 was based on the
reduced immunogenicity of E42 compared to E56 pancreatic
tissue when transplanted in conjunction with human lym-
phocytes into NOD-SCID mice. It should be noted that
adoptively transferred human lymphocytes tend to die of
apoptosis by the second month post-transplant, and previous
studies using this assay to monitor rejection of adult [42] or
fetal tissues [26] have shown that optimal rejection is attained
between 2 and 4 wk after infusion of hu-PBMCs. Thus, while
signiﬁcant reduction of insulin secretion accompanied by
marked inﬁltration of human T or B cells, as well as
macrophages, was found 4 wk after implantation of E56
tissue, only negligible peripheral inﬁltration of hu-PBMCs
was observed in the growing E42 implant, and no signiﬁcant
reduction of insulin secretion could be detected.
Another major parameter in deﬁning an ideal ‘‘window’’
for implantation of pig embryonic pancreas is the relative
ratio of endocrine and exocrine elements exhibited by the
growing tissue. Clearly, a minimal threshold of exocrine
activity in the developing implant is critical for long-term
preservation of the developing islets, which might be
susceptible to destruction by proteolytic enzymes if the
neighboring exocrine cells are predominant.
One approach to minimize the role of exocrine precursor
tissue in the implant is to cultivate fetal islet-like cell clusters
in short-term culture, as described by Korsgren et al. [43].
However, based on numerous studies demonstrating the
active involvement of the surrounding mesenchyme in the
pancreatic development and its role in endocrine cell
differentiation and proliferation [41,44–50], we elected to
transplant full embryonic pancreatic fragments. To minimize
the pretransplant ischemia time, no preparative manipula-
tions of the donor tissue were carried out, and fragments
were transplanted immediately after harvest. Interestingly,
prior to transplantation, exocrine elements could be detected
only at stages beyond E56. Most importantly, the growing E42
tissue after transplantation exhibited a predominance of
endocrine tissue, with only a minor exocrine component at 3
mo, and a complete dominance of islets without any trace of
exocrine tissue by the sixth month post-transplant. The
growing islets attained most of their size by the end of the
fourth month post-transplant, though dividing cells (stained
by Ki67) could be found up to the sixth month, when they
reached their ﬁnal size and stopped dividing, as indicated by
examination at later time points. This plateau in growth and
development is quantitatively measured by the insulin blood
levels between 6 and 10 mo post-transplant. The intriguing
predominance of endocrine tissue in the E42 implants might
be related to low initial levels of exocrine precursor cells, but
it may also be associated with unfavorable post-transplant
microenvironmental conditions required for exocrine line-
age development [51]. Interestingly, while second-trimester
human pancreas (15–20 wk of gestation) transplantation into
SCID mice showed similar diminished exocrine tissue in the
grafts [52], the recent observation of Castaing et al. [53] that
exocrine tissue is detected in early embryonic human
pancreas grafts (7.5–9.5 wk of gestation) upon transplantation
into SCID mice strongly indicates that the relative level of
exocrine precursors or their ability to be induced by the
stromal elements might vary between species.
The advantages of E42 porcine pancreatic tissue, as deﬁned
by its long-term growth potential, response to glucose
challenge, reduced immunogenicity, and endocrine/exocrine
ratio, were clearly exhibited when evaluating its curative
potential in two different models of hyperglycemia. In the
ﬁrst model, irreversible pancreatic damage was induced by
alloxan in long-term engrafted SCID mice. In the second
model, streptozotocin-treated mice were treated by implan-
tation of E42 tissue and treatment with exogenous insulin was
maintained until the grafts were sufﬁciently large to sustain
the mice in the absence of insulin treatment. In both models,
a period of 3 mo of growth was required to effectively
normalize glucose levels. Further studies are required to
deﬁne whether the use of growth factors in vitro or in vivo
might facilitate the growth of the embryonic implants so as to
achieve normalization at an earlier time after implantation
[54,55].
While the results in SCID mice are encouraging, the
immune barrier to xenografting, even when using early
embryonic tissue, represents a major challenge. It has been
known for over four decades that embryonic tissues are less
immunogenic than their adult counterparts [56]. Accordingly,
graft acceptance may reﬂect the progressive development of a
complex array of cell surface molecules and soluble factors
that determine immune recognition.
Clearly, because of the very low levels of human APCs in
the SCID recipients, the assay of immune rejection by
adoptively transferred hu-PBMCs employed in the present
study is largely biased towards detection of the direct
immune rejection mechanism and neglects the alternative
indirect mechanism, in which donor antigens are presented
by host APCs to host T cells (cross-priming). Therefore,
although the E42 implant is less immunogenic and is
relatively less susceptible to direct recognition than E56
tissue, it could still be rejected via the indirect pathway in
other murine models. Indeed, when transplanted in fully
immunocompetent mice, embryonic pig pancreatic tissues of
all gestational ages were promptly rejected. The mechanisms
underlying xenograft rejection of neovascularized embryonic
tissues, such as pancreatic fragments, have not been exten-
sively characterized to date. However, as shown in the present
study by transplantation into mouse strains with various
immunological defects, rejection is primarily dependent on T
cell responses. Other studies describing xenorejection of later
gestational age pig pancreas and adult pig islets also support
this conclusion [57,58]. In this context, it is likely that
immunosuppressive agents, such as costimulatory blocking
agents, directed against T cell activation and with minimal
impact on angiogenesis and/or embryonic growth and
development might be advantageous. Combined blockade of
the CD28-B7 (by CTLA4-Ig) and CD40-CD154 (by anti-
CD40L) costimulatory pathways has been shown to prevent
anti-donor antibody production and is associated with
increased host CD4þ T cell apoptosis in a concordant (rat
to mouse) xenotransplantation model [59]. However, in our
present study, when given during the ﬁrst week after
transplantation, the treatment protocol only delayed xenor-
ejection of the E42 pancreas for about 1 mo. In contrast,
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sulted in long-term graft survival with continuous production
of insulin accompanied by normalization of glucose levels in
diabetic mice. Thus, the pig embryonic tissue, which is
markedly distinct from adult vascularized organs such as pig
heart or kidney [60], might present immunological obstacles
comparable to, but not more difﬁcult than, those met with
allotransplantation. Very recently, Hering et al. [61] showed
that the immune suppression required to enable engraftment
of adult pig islets in cynomolgus monkeys was rather toxic,
leading to the death of six out of seven recipients that
achieved normoglycemia but that did not survive because of
the side effects associated with the immune suppression.
Similar conclusions were also suggested by Cardona et al. [62].
The use of E42 pig tissue, which is less immunogenic than
later gestational age tissues—not to mention adult tissue—
might potentially enable the use of less toxic immune
suppression protocols in the future.
The requirement for repeated treatment with costimula-
tory blockade agents suggests that permanent immune
tolerance to the growing embryonic implants is not attained
by this immunosuppressive treatment. However, the potential
of these or other costimulatory blockade agents to yield
permanent graft tolerance has not been fully investigated in
the embryonic tissue model, and our current experiments are
focused on deﬁning an optimal combination of costimulatory
blockade agents that might allow complete graft tolerance
without continued medication. Also, considering the throm-
botic activity recently exhibited by anti-CD40L antibodies in
nonhuman primates and in humans [63,64], it is important to
test alternative costimulatory blockade agents, such as anti-
LFA1, anti-ICOS1, or anti-CD48, which might effectively
replace anti-CD40L in our model. Taken together, our data
provide a proof of principle for the promising potential of
E42 embryonic pig pancreatic tissue as a novel source for
transplantation. Studies in a nonhuman primate model are
warranted in order to investigate the scope of reduced
immunogenicty, the issues of implant dose and transplanta-
tion site, and the functionality of the growing embryonic
pancreas. If successful, the use of embryonic porcine tissues
might offer an attractive source of unlimited pancreatic
tissue.
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Background. Diabetes is a growing global health problem. By 2030,
more than 300 million people around the world will have this chronic,
incurable disorder, double the current number. In non-diabetic people,
cells in the pancreas called beta cells release insulin, a hormone that
controls the level of sugar (glucose) in the blood. In diabetics, blood-
sugar levels become dangerously high either because the beta cells have
been destroyed so no insulin is made (type 1 diabetes, 5%–10% of all
cases) or because the cells that normally remove sugar from the blood
have become insensitive to insulin (type 2 diabetes). In particularly
severe cases of type 2 diabetes, the beta cells also stop releasing insulin.
People with type 2 diabetes can usually control their blood-sugar levels
through diet and exercise and by taking oral anti-diabetic drugs; people
with type 1 diabetes or severe type 2 diabetes have to replace the
missing insulin by injections. It is very important that diabetics keep their
blood-sugar levels as normal as possible to minimize the disorder’s
serious long-term complications. These include kidney failure, blindness,
nerve damage, and an increased risk of heart disease and strokes.
Why Was This Study Done? While individuals with type 1 diabetes can
control their blood-sugar levels pretty well by carefully monitoring their
life style and injecting insulin, potentially better control and fewer long-
term complications can be achieved by providing a new source of
insulin-producing cells through transplantation of pancreatic tissue from
a dead human donor. However, because there is not enough human
pancreatic tissue to treat all the diabetics who could benefit from such
transplants, researchers are investigating other sources of insulin-
producing cells. One possibility is pig pancreatic tissue. Glucose control
is very similar in pigs and humans, pig insulin injections have been used
for years to control diabetes, and pigs are in plentiful supply. However,
besides general concerns about xenotransplantation (that is, trans-
plantation from a foreign species such as pigs into humans), early
attempts to treat human diabetes by transplantation of pancreatic tissue
taken from pig embryos at late stages of gestation were not successful.
The researchers involved in this study had done earlier experiments that
suggested that the age of the pig donor tissue influences how well
transplantation into other species works. They therefore wanted to test
whether pancreatic tissue from younger pig embryos might work better
for pancreas transplants: they hoped that younger tissue would grow
and integrate better with the surrounding host tissue. Additionally, a
major concern with all transplantations is whether the transplanted cells
or tissue will be recognized as foreign and as such destroyed by the
host’s immune system. Because tissue from younger embryos is
generally less likely to trigger an immune reaction, the researchers
hoped that pancreatic tissue from younger pig embryos would be less
readily recognized as foreign by the human immune system.
What Did the Researchers Do and Find? They started by transplanting
pancreatic tissue from pig embryos of different ages into mice with
defective immune systems. Tissue taken about a third of the way
through gestation (that is, from embryos 42 or 56 days old) grew better
than tissue taken earlier or later, secreted more pig insulin over extended
periods of time, and was better at maintaining normal blood-sugar levels
when the beta cells of the host mice were destroyed. The researchers
then examined whether embryonic pig pancreatic tissue of different
ages triggered an immune reaction by seeing how well it survived when
human immune system cells were also transplanted into the mice. Tissue
from 42-day-old embryos came out best in this test too, suggesting that
there is little or no ‘‘direct’’ immune reaction by circulating immune cells
against pancreatic tissue from this stage. Finally, the researchers
transplanted pancreatic tissue of this age into diabetic mice with an
intact immune system. These mice rejected the transplants (presumably
through an ‘‘indirect’’ immune reaction), but that rejection could be
overcome when the recipient mice were treated with drugs that
suppressed the part of their immune system that is responsible for these
indirect immune reactions. (Human patients who receive a transplant are
usually treated with drugs that suppress direct and indirect immune
reactions.) When the mice were kept on the drugs, the grafts survived in
the long term, and the mice had normal blood-sugar levels once the
graft was well established.
What Do These Findings Mean? These results suggest that the exact
age of embryonic pig pancreatic tissue influences how well the
transplanted tissue grows and integrates into a host from a different
species (in this case, the mouse) and how strong an immune reaction it
triggers. Overall, these results support the notion that pig embryonic
pancreas tissue could potentially be a source of tissue for transplantation
into human patients with diabetes. The next steps in exploring this
possibility are likely to involve experiments in monkeys to find out how
much tissue should be implanted and where, and to check that the
transplanted tissue remains functional in these animals. The ability of the
42-day-old embryonic tissue to avoid direct immune rejection also needs
to be confirmed. And, ideally, the goal remains to find ways to avoid an
immune reaction altogether, so that recipients of transplants do not
need to be continually treated with drugs that suppress their immune
system (which makes them more susceptible to infections and can have
other side effects). Xenotransplantation has potential benefits and risks
and remains controversial. Studies like this one and others that seek to
better understand the risks and benefits are necessary to allow
reasonable decisions to be made.
Additional Information. Please access these Web sites via the online
versionofthissummaryathttp://dx.doi.org/10.1371/journal.pmed.0030215
  MedlinePlus pages on diabetes and on pancreas transplantation
  Information from the Juvenile Diabetes Research Foundation
International Description
  Wikipedia pages on diabetes, xenotransplantation, and pancreas
transplantation(note:Wikipediaisafreeonlineencyclopediathatanyone
can edit)
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